Millennium Management
SIOX

Millennium Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Millennium Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17,500
Closed -$963K – 4179
2017
Q3 		$963K Buy
+17,500
New +$2.95M ﹤0.01% 2535
2016
Q4 		– Sell
-11,063
Closed -$1.24M – 3853
2016
Q3 		$1.24M Buy
+11,063
New +$1.33M ﹤0.01% 2172

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Millennium Management's SIOX Position: Q1 2022 in Review

Millennium Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2022, closing a stake of 147,254 shares — an estimated $190K sold.

Millennium Management first reported a position in SIOX in Q2 2015 and held it in 21 quarters. The position peaked at $10.8M in Q1 2017. 41 funds tracked by Wall St. Rank hold SIOX as of Q1 2022.

  • Millennium Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Millennium Management sold 147,254 Sio Gene Therapies Inc. Common Stock shares in Q1 2022, an estimated $190K.
  • Millennium Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 21 quarters.
  • Millennium Management's Sio Gene Therapies Inc. Common Stock position peaked at $10.8M in Q1 2017.
  • 41 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2022.

Based on Millennium Management's 13F filing for Q1 2022, filed 16 May 2022.